Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 35

Results For "CE"

8096 News Found

Lupin receives USFDA approval for Tolvaptan Tablets
Drug Approval | April 24, 2025

Lupin receives USFDA approval for Tolvaptan Tablets

Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease


Eugia Pharma receives USFDA approval for Dasatinib Tablets
Drug Approval | April 24, 2025

Eugia Pharma receives USFDA approval for Dasatinib Tablets

Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia


Nureca receives approval for new manufacturing facility
News | April 23, 2025

Nureca receives approval for new manufacturing facility

This unit will focus on the manufacturing of health and wellness equipment


Paras Healthcare introduces radiation oncology facility at Ranchi
Healthcare | April 23, 2025

Paras Healthcare introduces radiation oncology facility at Ranchi

The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home


Gujarat CM Bhupendra Patel inaugurates 217-bed cancer hospital in Ahmedabad
Healthcare | April 22, 2025

Gujarat CM Bhupendra Patel inaugurates 217-bed cancer hospital in Ahmedabad

The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat


FUJIFILM launches advanced therapeutic endoscopy system in India
News | April 22, 2025

FUJIFILM launches advanced therapeutic endoscopy system in India

The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing


AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer
News | April 22, 2025

AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care


Aptar commences clinical study to accelerate FDA approval of SmartTrack
News | April 19, 2025

Aptar commences clinical study to accelerate FDA approval of SmartTrack

SmartTrack aims to reduce the need for clinical studies in generic drug product approvals


Rockwell Automation empowers NKP Pharma achieve regulatory compliance
Digitisation | April 17, 2025

Rockwell Automation empowers NKP Pharma achieve regulatory compliance

By integrating Rockwell Automation’s FactoryTalk Optix, NKP Pharma has achieved compliance with USFDA 21 CFR Part 11